|
Software Firm Must Seek PMA, FDA Warning Letter States
The FDA has escalated a long-simmering dispute with Israeli-owned software developer NeuroTrax about the proper classification of its MindStreams cognitive health assessment tool, telling the company in a warning letter it must seek Class III status or halt marketing the product.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives